Skip to content
value.today

Conatus Pharmaceuticals Inc

Total raised
$36 M
4 rounds on record
Latest round
$5 M
Jul 2022
First round on record
Mar 2010
Today
Private
No later event on record

Funding rounds

4 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Conatus Pharmaceuticals Inc
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2022$5 MNo. 4$2 to $10 million

Conatus Pharmaceuticals Inc: Raise no. 4, Jul 2022

Investors in this round

1 investor had bought by the notice of Jul 26, 2022: 1 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Conatus Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
$486,132
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks sales commissions as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gail K. Naughton · Executive Officer
  • Joyce J. Reyes · Executive Officer
  • Martin K. Latterich · Executive Officer
  • Steven J. Mento · Executive Officer, Director
  • Susan A. Knudson · Executive Officer
  • Brian L. Satz · Director
  • Daniel L. Kisner · Director
  • David H. Crean · Director
  • Jonathan H. Jackson · Director
  • Rochelle L. Fuhrmann · Director
  • Susan L. Windham-Bannister · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • H.C. Wainwright & Co., LLC (CRD 375) · New York, New YorkSold in NY

Remarks in the notice

  • On fees: “Company has agreed to pay Wainwright (i) fee equal to 7.0% of the gross proceeds received by the Company, (ii) a management fee equal to 1.0% of the gross proceeds received by the Company; and (iii) $85,000 for non-accountable expenses.”
  • On the amounts: “Consists of: (i) (A) a pre-funded warrant to purchase 1,774,309 shares; (B) a Series A warrant to purchase 1,774,309 shares; and (C) a Series B warrant to purchase 1,774,309 shares; and (ii) placement agent warrants to purchase 124,202 shares.”

Signed by Susan A. Knudson, Chief Financial Officer. Source: SEC Form D, newest notice filed Jul 26, 2022. Read the notice at the SEC.

optionsSEC
May 2013$1 MNo. 3Under $2 million

Conatus Pharmaceuticals Inc: Raise no. 3, May 2013

Investors in this round

21 investors had bought by the notice of Jun 13, 2013: 21 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Conatus Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
$1
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alfred P. Spada, Ph.D. · Executive Officer
  • Charles J. Cashion · Executive Officer
  • Gary C. Burgess · Executive Officer
  • Steven J. Mento, Ph.D. · Executive Officer, Director
  • David F. Hale · Director
  • Harold H. Van Wart, M.D. · Director
  • James H. Scopa · Director
  • Louis H. Lacasse · Director
  • Marc H. Perret · Director
  • Paul H. Klingenstein · Director
  • Shahzad H. Malik, M.D. · Director
  • William F. Gerber, M.D. · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “The offering includes promissory notes and warrants to purchase 1,124,026 shares of preferred stock at a price of $0.0001 per share. None of such warrants have yet been exercised and such warrants may never be exercised.”

Signed by Charles J. Cashion, Sr. VP of Finance, CFO & Secretary. Source: SEC Form D, newest notice filed Jun 13, 2013. Read the notice at the SEC.

debt, optionsSEC
Feb 2011$25 MNo. 2$10 to $50 million

Conatus Pharmaceuticals Inc: Raise no. 2, Feb 2011

Investors in this round

16 investors had bought by the notice of Feb 17, 2011: 16 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Conatus Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$25 M of $25 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alfred P. Spada · Executive Officer
  • Charles J. Cashion · Executive Officer
  • Jennifer Giottonini Cayer · Executive Officer
  • Steven J. Mento · Executive Officer, Director
  • David F. Hale · Director
  • Harold F. Van Wart · Director
  • Louis F. Lacasse · Director
  • Marc F. Peret · Director
  • Paul F. Klingenstein · Director
  • Shahzad F. Malik · Director
  • William J. Gerber · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Charles J. Cashion, Senior Vice President Finance, CFO and Secretary. Source: SEC Form D, newest notice filed Feb 17, 2011. Read the notice at the SEC.

equitySEC
Mar 2010$5 MNo. 1$2 to $10 million

Conatus Pharmaceuticals Inc: Raise no. 1, Mar 2010

Investors in this round

15 investors had bought by the notice of Oct 28, 2010: 15 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 14 investors are named for Conatus Pharmaceuticals Inc as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $5 M offered
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Alfred P. Spada · Executive Officer
  • Charles J. Cashion · Executive Officer
  • Jennifer Giottonini Cayer · Executive Officer
  • Steven J. Mento · Executive Officer, Director
  • David F. Hale · Director
  • Harold F. Van Wart · Director
  • Marc F. Peret · Director
  • Paul F. Klingenstein · Director
  • Shahzad F. Malik · Director
  • William J. Gerber · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Total Offering Amount and Total Amount Sold is the sum of the first closing and second closing which occurred on March 5, 2010 and October 15, 2010, respectively.”

Signed by Charles J. Cashion, SVP Finance, CFO and Secretary. Source: SEC Form D, newest notice filed Oct 28, 2010. Read the notice at the SEC.

debt, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Conatus Pharmaceuticals Inc chose not to state its revenue in its newest notice of a funding round (Jul 2022).

    SEC Form D · Jul 2022

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2022

That is all the official record says: Conatus Pharmaceuticals Inc has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

14 named in official filings. Open an investor to see everything it has backed.

Investors in Conatus Pharmaceuticals Inc
InvestorKindAmountRoundRoleSource
Aberdare GP III, L.L.C.Othernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Aberdare Partners III LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Aberdare Ventures III LPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Advent Venture Partners LLPVenture capitalnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
Cooperative Gilde Healthcare II U.a.Personnot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM Asset Management Investors BV4 LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM Asset Management Investors BV5 LLCFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM BioVentures IV GmbH & Co. Beteiligungs KGVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM BioVentures IV GP LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM BioVentures IV LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM BioVentures IV QP LPVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM Bioventures V GP LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM Bioventures V LLCVenture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3
MPM Bioventures V, L.P.Venture capitalnot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2013)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 21 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Conatus Pharmaceuticals Inc
NameRoleNamed in
Gail K. NaughtonExecutive officerJul 2022
Joyce J. ReyesExecutive officerJul 2022
Martin K. LatterichExecutive officerJul 2022
Steven J. MentoExecutive officerJul 2022
Susan A. KnudsonExecutive officerJul 2022
Alfred P. Spada, Ph.D.Executive officerJun 2013
Charles J. CashionExecutive officerJun 2013
Gary C. BurgessExecutive officerJun 2013
Steven J. Mento, Ph.D.Executive officerJun 2013
Alfred P. SpadaExecutive officerFeb 2011
Jennifer Giottonini CayerExecutive officerFeb 2011
Brian L. SatzDirectorJul 2022
Daniel L. KisnerDirectorJul 2022
David H. CreanDirectorJul 2022
Jonathan H. JacksonDirectorJul 2022
Rochelle L. FuhrmannDirectorJul 2022
Steven J. MentoDirectorJul 2022
Susan L. Windham-BannisterDirectorJul 2022
David F. HaleDirectorJun 2013
Harold H. Van Wart, M.D.DirectorJun 2013
James H. ScopaDirectorJun 2013
Louis H. LacasseDirectorJun 2013
Marc H. PerretDirectorJun 2013
Paul H. KlingensteinDirectorJun 2013
Shahzad H. Malik, M.D.DirectorJun 2013
Steven J. Mento, Ph.D.DirectorJun 2013
William F. Gerber, M.D.DirectorJun 2013
Harold F. Van WartDirectorFeb 2011
Louis F. LacasseDirectorFeb 2011
Marc F. PeretDirectorFeb 2011
Paul F. KlingensteinDirectorFeb 2011
Shahzad F. MalikDirectorFeb 2011
William J. GerberDirectorFeb 2011